HUTCHMED Announces Savolitinib sNDA Accepted in China for Tr

— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If...

Related Keywords

Hong Kong , China , Poland , United States , Shanghai , Polish , American , Ben Atwell , Zhou Yi , Atholl Tweedie , Astrazeneca , China Limited , European Lung Cancer Congress On , American Cancer Society , National Reimbursement Drug List , Stock Exchange Of Hong Kong , European Lung Cancer Congress , Nasdaq , International Agency For Research On Cancer , World Health Organization , Exchange Commission , Single Institution Study , China National Medical Products Administration , Linkedin , New Drug Application , Lung Cancer , Securities Litigation Reform Act , Stock Exchange , Hong Kong Limited , International Agency , Clinical Oncology Provisional Opinion , Epidermal Growth Factor Receptor , Mutation Testing , Kinase Inhibitor , Histological Samples , Small Cell Lung Cancer , Systematic Review , Intj Clin Exp , Mutated Advanced Non Small Cell Lung , Positive Lung , Clinical Oncology , Markets ,